Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.3 pts more than Nifty Microcap 250 and 14.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lincoln Pharmaceuticals reported strong Q3 FY26 results with consolidated revenue from operations rising 13.49% year-on-year to Rs. 166.32 crore, driven by robust demand across cardiac, diabetic, dermatology and ENT segments. Net profit surged 37.70% YoY to Rs. 28.60 crore, while EBITDA grew 18.73% to Rs. 38.74 crore, reflecting healthy margin expansion. For the nine months ended December 2025, revenue grew 6.31% to Rs. 483.75 crore and net profit rose 7.76% to Rs. 76.26 crore. EPS for Q3 stood at Rs. 14.28 versus Rs. 10.37 in Q3 FY25. The company maintains a debt-free balance sheet and is targeting Rs. 1,000 crore revenue over the next three years, supported by 15-18% annual growth ambitions and exports to 60+ countries.
Positive for shareholders — strong double-digit profit growth and EBITDA margin expansion signal healthy operational performance. CRISIL has reaffirmed its A/Stable rating, FII holding is at 4.70%, and the debt-free status combined with ambitious growth targets supports a constructive outlook for the stock.